Select a Region North America

Expertise

Gwilym Owen

Gwilym Owen

Senior Consultant, Global Regulatory Consulting

Expertise:

Consulting (Strategy Management & Regulatory), Digital Health, Digital Medicine, Medical Devices, Regulatory Compliance

Gwilym is a seasoned regulatory professional with 15+ years of experience in Software as a Medical Device (SaMD). His expertise spans startups to large corporations, covering manufacturers and distributors. Gwilym has contributed significantly to various diagnostic and therapeutic areas, including acute stroke, cancer, and liver fibrosis. Proficient in different platform types, he has authored submissions for global markets, including the US, EU, Turkey, Japan, Korea, Australia, Brazil, and Canada. Gwilym’s leadership in authoring pre-submissions, 510(k)s, and EU Technical Files for Class I, II, IIa, and IIb devices, along with his adept negotiation skills with EU notified bodies and FDA interactions, highlights his impact in the regulatory landscape. His commitment to ensuring compliance with industry standards, such as IEC 62304/82304 and ISO 14971, underscores his dedication to advancing medical device technologies globally.

Articles by Gwilym Owen

Clinical Data Portability for Regulatory Submissions Across Global Markets

Navigating the regulatory landscape for medical devices is complex, especially in relation to using clinical study data from overseas to support regulatory approval and reimbursement in the U.S., EU and U.K. The key question many companies face is whether their completed clinical study in another country can be leveraged for regulatory processes in these regions. While it is possible, the answer is nuanced and depends on various factors such as specific indications, risk-benefit profiles, and the type and scope of clinical data. In this comprehensive analysis, we delve into the intricacies of regulatory acceptance in these three major markets and examine primary considerations, including the role of individual reviewers, the […]

Updated Guidance May Ease MDR Transition for SaMD Manufacturers

The regulation of medical devices in the EU has been chaotic since the implementation of Regulation (EU) 2017/745, known as the Medical Device Regulation (MDR). This upheaval has been particularly challenging for manufacturers facing a backlog of MDR transition applications and a dwindling number of Notified Bodies equipped to handle them. As a result, companies holding Medical Device Directive—Council Directive 93/42/EEC (MDD) CE Certificates have been anxiously awaiting their transition to the MDR before the 2024 deadline for MDD certificate recognition. Thankfully, the European Commission has provided some relief. If an application with a Notified Body is in place before the 2024 deadline, the EU has extended the transitional provisions […]

The Looming Legacy of Software as a Medical Device (SaMD) Misclassification Under Medical Device Directive (MDD)

Regulation (EU) 2017/745, the Medical Device Regulation (MDR), sent shockwaves through the industry with its stricter oversight and transparency demands. While the implementation challenges like delays, notified body capacity, and EUDAMED implementation have dominated discussions, a potentially bigger issue lurks for software as a medical device (SaMD) previously classified as Class I under the Medical Device Directive (MDD). The structure of the MDD allowed for broad and varied interpretations of the Directive, and some SaMD manufacturers relied upon this leeway to self-classify devices as low-risk Class I. Now, with the MDR in effect, these devices are stuck in a loophole and face serious challenges in meeting the rigors of the […]

An Impactful Year for Global Regulation of Digital Health

2023 was a busy year with FDA and EU advancing key initiatives focused on AI/ML, cybersecurity, global harmonization, real-world evidence, and pharma companion apps…and more is coming in 2024. While 2023 brought its share of challenges for the digital health sector, it ultimately served as a pivotal year for shaping the future of how digital medical devices are developed and regulated. Many new regulations and policies were introduced or issued after years in the making, and others were reactions to sweeping technological and methodological industry advancements that required broad changes in the global regulatory environment. First, we’ll zoom in on key global initiatives poised to shake up digital health. Then, […]

Interested in scheduling a meeting or speaking event?

お問い合わせ